Table 2.

Comparison of vision and macular thickness at different time points between the innovator and biosimilar ranibizumab

Variable	Innovator RBZ (n = 264)	Biosimilar RBZ (n = 69)	p value
BCVA comparisons (logMAR)
Baseline	0.64 ± 0.39	0.71 ± 0.42	0.18
1 month	0.48 ± 0.29**	0.55 ± 0.30**	0.32
3 months	0.49 ± 0.39	0.49 ± 0.25	0.72
6 months	0.47 ± 0.31	0.50 ± 0.29	0.61
9 months	0.37 ± 0.32 (n = 134)	0.47 ± 0.27 (n = 41)	0.17
12 months	0.38 ± 0.32 (n = 123)	0.44 ± 0.26 (n = 35)	0.25
Final visual acuity*	0.40 ± 0.36	0.44 ± 0.26	0.39
BCVA	0.24 ± 0.40	0.26 ± 0.34	0.71
% 3 line loss	18 (7%)	1 (1.5%)	0.14
% 3 line gain	114 (43%)	32 (46%)	0.63
CMT comparisons (μm)
Baseline	457 ± 172	434 ± 153	0.40
1 month	364 ± 152**	343 ± 126**	0.88
3 months	334 ± 147**	306 ± 97**	0.51
6 months	346 ± 162	326 ± 159	0.62
9 months	342 ± 161 (n = 134)	316 ± 150 (n = 41)	0.45
12 months	341 ± 161 (n = 134)	318 ± 150 (n = 41)	0.58
CMT final*	337 ± 160	328 ± 137	0.83
CMT	120 ± 196	105 ± 187	0.69

* Any time period

** p < 0.05 compared to previous time point

RBZ ranibizumab, CMT central macular thickness